Korean Pharma Earnings Diverge: JW Surges 33% as Huons and Medytox Profits Slide

Korea’s mid-cap pharmaceutical sector delivered sharply split second-quarter scorecards, with JW Pharmaceutical posting a 32.7% jump in operating profit to 33.7 billion won while Huons saw its profit collapse 77.6% to 2.9 billion won and Medytox slipped 24.6% to 4.8 billion won. Medical AI firm Lunit, reporting on a first-half basis, grew revenue 23% to 45.77 billion won — a reminder that the growth stories in Korean healthcare are increasingly found outside conventional drugmaking.

One Sector, Three Different Quarters

The latest disclosures underline how little the label “K-pharma” now says about any individual company’s trajectory. JW Pharmaceutical, which reported on a standalone basis and filed a related investor disclosure with the Financial Supervisory Service’s DART system, stood out as the quarter’s clear winner among the four, expanding operating profit by roughly a third from the same period a year earlier.

At the other end, Huons retained only a fraction of its year-ago profitability. A 77.6% decline in consolidated operating profit — to 2.9 billion won — is the kind of drop that typically reflects margin pressure across core lines rather than a one-off accounting item, and it leaves the company with the weakest bottom line of the group by a wide margin.

Medytox, the botulinum toxin specialist, landed in between. Its consolidated operating profit of 4.8 billion won marked a 24.6% year-on-year decline — a meaningful erosion, but nowhere near the scale of Huons’ contraction.

Lunit Extends the AI Growth Narrative

Lunit’s numbers came framed differently — half-year revenue rather than quarterly profit — but the direction was unambiguous. Consolidated sales of 45.77 billion won for the first six months represented 23% growth from a year earlier. For a company selling AI-based cancer screening and diagnostics software, top-line expansion remains the metric investors watch most closely, and the first-half figure keeps Lunit’s growth story intact even as traditional manufacturers around it struggle to defend margins.

Health-Adjacent Demand Is Still Expanding

The mixed corporate results arrive against a backdrop of steady growth in Korea’s broader health and hygiene economy. The Ministry of Food and Drug Safety — the same regulator that oversees the drugmakers above — put the country’s sanitary products market at 3.1492 trillion won for 2025, up 9.7% from the previous year. Demand across regulated health-adjacent categories, in other words, is not the problem; the divergence in earnings reflects company-specific dynamics in product mix, competition, and cost structure rather than a shrinking market.

What the Divergence Means

For investors, the quarter reinforces a stock-picker’s market in Korean healthcare. Profit growth is available — JW Pharmaceutical proved that — but it is unevenly distributed, and consolidated results at Huons and Medytox show how quickly margins can compress. The clearest structural tailwind sits with revenue-stage players like Lunit, whose 23% first-half growth contrasts with the profit volatility of established manufacturers. The second half will test whether JW can sustain its momentum and whether Huons’ steep decline marks a trough or the start of a longer reset.